Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as parainfluenza virus type 3 vaccine (PIV3)
parainfluenza virus type 3 vaccine · 1 trial · 3 indications
Number of participants experiencing immediate unsolicited systemic AEs
Number of participants reporting: \- injection site reactions: pain, erythema and swelling
Number of participants reporting: * systemic reactions: fever, headache, fatigue, myalgia, arthralgia and chills
Number of participants experiencing unsolicited AEs
Number of participants experiencing SAEs regardless of causality
Number of participants experiencing AESIs regardless of causality
Number of participants experiencing related SAEs regardless of causality
Number of participants experiencing related AESIs regardless of causality
Number of participants experiencing related fatal SAEs regardless of causality
Number of participants with biological safety assessment values out of normal range (as per the laboratory performing the test, including shift from baseline values)
| Arm | Type | Description |
|---|---|---|
| PIV3 Dose 1 | EXPERIMENTAL | Participants will receive a single intramuscular (IM) injection at Day 1 |
| PIV3 Dose 2 | EXPERIMENTAL | Participants will receive a single intramuscular (IM) injection at Day 1 |
| PIV3 Dose 3 | EXPERIMENTAL | Participants will receive a single intramuscular (IM) injection at Day 1 |
| PIV3 Dose 4 | EXPERIMENTAL | Participants will receive a single intramuscular (IM) injection at Day 1 |
| RSV/hMPV /PIV3 Formulation 1 | EXPERIMENTAL | Participants will receive a single intramuscular (IM) injection at Day 1 |
| RSV/hMPV Formulation 1 | EXPERIMENTAL | Participants will receive a single intramuscular (IM) injection at Day 1 |
| RSV/hMPV Formulation 2 | EXPERIMENTAL | Participants will receive a single intramuscular (IM) injection at Day 1 |
| RSV vaccine 1 | EXPERIMENTAL | Participants will receive a single intramuscular (IM) injection at Day 1 |
| RSV vaccine 2 | EXPERIMENTAL | Participants will receive a single intramuscular (IM) injection at Day 1 |
| Name | Type | Description |
|---|---|---|
| parainfluenza virus type 3 vaccine (PIV3) | BIOLOGICAL | Pharmaceutical form:Frozen liquid solution -Route of administration:Intramuscular |
| RSV/hMPV/PIV3 vaccine | BIOLOGICAL | Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular |
| RSV/hMPV vaccine | BIOLOGICAL | Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular |
| RSV vaccine 1 | BIOLOGICAL | Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular |
| RSV vaccine 2 | BIOLOGICAL | Pharmaceutical form:Frozen liquid solution-Route of administration:Intramuscular |
Inclusion Criteria: * Aged 60 years or older on the day of inclusion (means from the means from the day of the 60th birthday). * Informed consent form (ICF) has been signed and dated * A female participant is eligible to participate if she is of non-childbearing potential. To be considered of non-c...
The parainfluenza virus type 3 vaccine is an investigational vaccine developed by Sanofi that targets respiratory syncytial virus infection. It is a Phase 1 candidate studied in adults aged 60 years and older. The vaccine candidate also covers human metapneumovirus and parainfluenza virus type 3 in a single formulation.
The parainfluenza virus type 3 vaccine is being studied for the prevention of respiratory syncytial virus infection, along with metapneumovirus infection and parainfluenzae virus infection. It is designed for use in adults aged 60 years and older. It remains investigational and has not been approved for use.
Sanofi, which trades under the ticker SNY, is the developer of the parainfluenza virus type 3 vaccine. The company is studying the candidate in older adults as part of its vaccine pipeline. Sanofi holds the program and conducted the Phase 1 trial in Australia.
The parainfluenza virus type 3 vaccine is in Phase 1 development. Its single clinical trial has been completed, and no trials are currently active. The candidate is investigational and has not been approved by the FDA or any other regulator based on the available information.
The parainfluenza virus type 3 vaccine has been studied in one clinical trial, NCT06604767, titled Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older. The Phase 1 trial enrolled 390 participants in Australia, was randomized, double-blind, and controlled, and is now completed.
Yes, the parainfluenza virus type 3 vaccine is also known as parainfluenza virus type 3 vaccine (PIV3). PIV3 is the abbreviated name used for the same Sanofi vaccine candidate. Both names refer to the same Phase 1 investigational product studied in adults aged 60 years and older.